BIOG vs. GSS, FCSS, CGT, JPE, FSV, IEM, ASHM, TRY, BRWM, and RICA
Should you be buying The Biotech Growth Trust stock or one of its competitors? The main competitors of The Biotech Growth Trust include Genesis Emerging Markets Fund (GSS), Fidelity China Special (FCSS), Capital Gearing (CGT), JPMorgan Elect plc - Managed Growth (JPE), Fidelity Investment Trust - Fidelity Special Values (FSV), Impax Environmental Markets (IEM), Ashmore Group (ASHM), TR Property Investment Trust (TRY), BlackRock World Mining Trust (BRWM), and Ruffer Investment (RICA). These companies are all part of the "asset management" industry.
The Biotech Growth Trust vs.
Genesis Emerging Markets Fund (LON:GSS) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
The Biotech Growth Trust has a net margin of 92.85% compared to Genesis Emerging Markets Fund's net margin of 0.00%. The Biotech Growth Trust's return on equity of 21.57% beat Genesis Emerging Markets Fund's return on equity.
The Biotech Growth Trust received 20 more outperform votes than Genesis Emerging Markets Fund when rated by MarketBeat users. Likewise, 64.06% of users gave The Biotech Growth Trust an outperform vote while only 62.00% of users gave Genesis Emerging Markets Fund an outperform vote.
The Biotech Growth Trust has lower revenue, but higher earnings than Genesis Emerging Markets Fund. Genesis Emerging Markets Fund is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.
In the previous week, The Biotech Growth Trust had 1 more articles in the media than Genesis Emerging Markets Fund. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Genesis Emerging Markets Fund. The Biotech Growth Trust's average media sentiment score of 1.90 beat Genesis Emerging Markets Fund's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.
28.6% of The Biotech Growth Trust shares are owned by institutional investors. 0.7% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
The Biotech Growth Trust beats Genesis Emerging Markets Fund on 10 of the 12 factors compared between the two stocks.
Get The Biotech Growth Trust News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Biotech Growth Trust Competitors List
Related Companies and Tools
This page (LON:BIOG) was last updated on 1/21/2025 by MarketBeat.com Staff
